Epiphany races ahead after reaching £30m deals milestone

24 MAR 2016

Manchester-based Epiphany, which was founded by managing partner Tim Dempsey in 2011, reached a £30m milestone with its latest transactions and has further deals worth £3.5m nearing completion.

The head of corporate finance house Epiphany Capital has hailed the strength of the north west’s technology and life sciences sectors as it enjoys its busiest-ever start to a year.

Manchester-based Epiphany, which was founded by managing partner Tim Dempsey in 2011, reached a £30m milestone with its latest transactions and has further deals worth £3.5m nearing completion.

Tim advised on January’s £5.5m investment boost from Oxford Capital, Draper Esprit and Partech Ventures for Manchester-based PushDoctor, which has developed an online, on-demand GP surgery.

He also put together a £775,000 growth capital deal for Leeds-based Instrumentel, which develops electronics systems for precision measurement in the rail industry.

The deal was supported by Alycidon Capital and Manchester Venture Partners, which is Epiphany’s sidecar fund.

Beyond the north west, Tim has advised companies including SuperCarers.com, a marketplace which connects families with expert home carers, and Faceshift, a Zurich-based motion capture company behind technology which features in the latest Star Wars film.

Tim said Epiphany’s pipeline remains strong, adding: “We’re seeing a greater level and higher quality of deal flow across northern England. The north west in particular has really upped its game in technology and life sciences.

“It’s a really exciting region in which to operate and I’m confident that we can bring more top-tier venture capital to the region which will, in turn help the region to produce more global leaders.”

Epiphany has now advised on 23 fundraising deals in the technology and life sciences sectors, with a focus on fast-growing, early-stage companies that have the ability to make a significant impact in their markets.

Tim said: “Our strategy is to become closely aligned with these companies and utilise our strong relationships with the venture capital community to put deals together, allowing management teams to concentrate on growing their businesses while we take care of their funding requirements.

“Our main focus is on ‘enabling’ technologies in financial services, consumer health, connected medical devices, e-commerce, artificial intelligence and the internet of things – all areas which reflect our changing lifestyles.”

Epiphany is supported by a team of experienced advisers that includes Dr Ian Evetts, a former evaluations director at AstraZeneca.